| |
Recent Weight Changes Studies
|
| |
| |
This remains an ongoing hot topic with more research needed to understand but there has been a lot of research on this subject. Potential causes have been reported income of these studies but I think remain elusive. Weight after starting PrEP in the DISCOVER Trial is below. Both the Sax study and Grace McComsey reporting found around 30% experienced increased weight, so importantly most do not gain significant weight, and a small percent gain a very inordinate amount of weight.
Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF) - (10/28/22)
CROI 2020: Grace McComsey: Understanding Who Does and Does Not Gain Weight with Integrase Inhibitors (INSTI)
Weight change associated with switching to bictegravir/emtricitabine/tenofovir alafenamide in virally suppressed people with HIV Weight Climbs With Switch to Bictegravir Across Baseline Regimens - - (10/22/22)
Weight changes with PrEP - TAF vs TDF in DISCOVER PrEP Trial - Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Risk Factors and Metabolic Implications of Integrase Inhibitor Associated Weight Gain - (10/22/22)
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials Clinical Infectious Diseases 15 September 2020 Paul E. Sax et al.
IMPROVED METABOLIC PARAMETERS AFTER SWITCHING FROM TAF-BASED 3- OR 4-DRUG REGIMEN TO THE 2-DRUG REGIMEN OF DTG/3TC (DOLUTEGRAVIR/LAMIVUDINE): THE TANGO STUDY
IAC 2020 - OPERA Study, Paddy Mallon: Weight gain before and after switch from TDF to TAF - (07/07/20)
IAC 2020 Virtual: Changes in Body Mass Index Over Time in Persons With and Without HIV - Kaiser - (07/27/20)
The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection. - (07/15/20)
The predicted risk of adverse pregnancy outcomes from treatment-induced obesity in the ADVANCE trial. - Dolutegravir With TAF or TDF Could Increase Adverse Pregnancy Outcomes - (07/15/20)
IAC2020: Weight/Body Mass Index Gains Following Initiation of Integrase Strand Transfer Inhibitor Versus Protease Inhibitor Among People Living With Human Immunodeficiency Virus in the United States - (07/09/20)
Glasgow: Fat distribution and density in PLWH with ≥5% weight gain - (11/03/20)
WEIGHT CHANGES AFTER SWITCH TO DORAVIRINE/LAMIVUDINE/TDF IN THE DRIVE-SHIFT TRIAL - (07/07/20)
Long-term Treatment Efficacy and Safety Following Switch to Doravirine/ Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF): Week 144 Results of the DRIVE-SHIFT Trial - (10/08/20)
ISLATRAVIR (ISL, MK-8591) SAFETY ANALYSIS THROUGH WEEK 48 FROM A PHASE 2 TRIAL IN TREATMENT NAÏVE ADULTS WITH HIV-1 INFECTION - (07/08/20)
Weight change among treatment naive women initiating dolutegravir in the ARIA study - (07/11/20)
Weight gain and hyperglycemia during the dolutegravir transition in Africa - (07/10/20)
CROI 2020: Predicted Rise in Diabetes Risk With TAF/FTC+DTG Versus TDF/FTC+DTG
Associations with weight change and patient reported outcomes after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) - (10/15/20)
Starting or switching to bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study - (10/09/20)
Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 72 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449) - (10/09/20)
IAC 2020: Aging, Comorbidities, weight changes, HCV-MSM, NAFLD, Challenges-Unmet Needs of elderly PLWH - (08/24/20)
Weight Gain at IAC 2020
The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection. - (07/15/20)
The predicted risk of adverse pregnancy outcomes from treatment-induced obesity in the ADVANCE trial. - Dolutegravir With TAF or TDF Could Increase Adverse Pregnancy Outcomes - (07/15/20)
Weight change among treatment naive women initiating dolutegravir in the ARIA study - (07/11/20)
Weight gain and hyperglycemia during the dolutegravir transition in Africa - (07/10/20)
WEIGHT CHANGES AFTER SWITCH TO DORAVIRINE/LAMIVUDINE/TDF IN THE DRIVE-SHIFT TRIAL - (07/07/20)
Weight gain before and after switch from TDF to TAF - (07/07/20)
People With HIV Gaining Weight 3 Times Faster Than HIV-Negatives in US - Mark Mascolini (07/06/20)
Early Weight Gain Up to 4.5 Kg/Year With Switch From TDF to TAF: Data Suggest Independent Effect of TAF on Weight - (07/06/20)
Only Small Weight Gains After Trial Switch to Doravirine/3TC/TDF - (07/06/20)
ISLATRAVIR (ISL, MK-8591) SAFETY ANALYSIS THROUGH WEEK 48 FROM A PHASE 2 TRIAL IN TREATMENT NAÏVE ADULTS WITH HIV-1 INFECTION - (07/08/20)
Islatravir Safety Through 48 Weeks With Doravirine in Phase 2 Trial - (07/09/20)
Doravirine, Islatravir at AIDS2020 IAC - (07/09/20)
Weight/Body Mass Index Gains Following Initiation of Integrase Strand Transfer Inhibitor Versus Protease Inhibitor Among People Living With Human Immunodeficiency Virus in the United States - (07/09/20)
|
|
| |
| |
|
|
|
